Noticias y Actividades de Candel Therapeutics
Presencia
Ejecutivos
Ver el organigrama con sus 29 ejecutivos principales
Biografías más buscadas en Candel Therapeutics
- Paul-Peter Tak, Director, President and Chief Executive Officer
- Chris Martell, Director
- Edward Benz, Director
Recientes movimientos de ejecutivos en Candel Therapeutics
- Mark Sims, se ha incorporado a la empresa como Chief Commercial Officer (noticia publicada el 25 de junio de 2026).
- Allison Nylen que ha sido Director, Finance, ha ascendido a Corporate Controller (noticia publicada el 14 de enero de 2026).
- Kristin Kennedy, Corporate Controller, ha dejado la empresa (noticia publicada el 14 de enero de 2026).
Crear su alerta
para seguir los movimientos de los ejecutivos en Candel Therapeutics.
Biotecnología
Candel Therapeutics tiene 2.428 competidores entre los que se incluyen Lonza (Suiza), Vertex Pharmaceuticals (Estados Unidos) y Eurofins (Luxemburgo).
Popular M&A news in Biotecnología
- Eli Lilly has announced the acquisition of AtaiBeckley (publicado el 17 de julio de 2026).
- GSK ha Nuvalent adquirido (publicado el 17 de julio de 2026).
- Clearside Biomedical has gone out of its bankruptcy protection (publicado el 15 de julio de 2026).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Candel Therapeutics
- Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer | Candel Therapeutics, Inc
- Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting | Candel Therapeutics, Inc
- Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Candel Therapeutics, Inc
- Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Candel Therapeutics, Inc
- Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors | Candel Therapeutics, Inc
- Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights | Candel Therapeutics, Inc
- Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting | Candel Therapeutics, Inc
- Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Candel Therapeutics, Inc
- Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston | Candel Therapeutics, Inc
- Candel Therapeutics Announces Proposed $100 Million Public Offering | Candel Therapeutics, Inc
- View more press releases Close
Redes sociales sobre Candel Therapeutics
- Candel Therapeutics en Wikipedia, Google News y Yahoo Finance
- Candel Therapeutics en LinkedIn, Twitter y YouTube
